INTRODUCTION
============

Breast cancer, which has one of the highest rates of prevalence and survival among tumor-related conditions, is one of the most vigorously studied diseases in the field of psycho-oncology \[[@b1-pi-2017-07-26]\]. The incidence rate of *in situ* breast cancer in women age 50 or under increased by 1.9% annually between 1998 and 2010, while breast cancer death rates decreased by 34% between 1990 and 2010 in the United States \[[@b2-pi-2017-07-26]\]. One of the reasons for such a trend is that advances in screening methods and oncological treatment have enabled both early detection and increased survival rates \[[@b3-pi-2017-07-26]\].

Increased long-term survival rates have directed the attention of researchers and clinicians toward quality of life for patients with breast cancer, who often undergo various complementary therapies, such as radiotherapy, chemotherapy, and hormone therapy in addition to surgery. Such intensive treatment often results in increased psychological symptoms such as postoperative depression, anxiety, distorted body image, and reduced self-esteem. In particular, symptoms of depression and anxiety in patients with breast cancer not only impact overall quality of life by reducing social function and social adaptation but also influence the progression and prognosis of cancer itself \[[@b4-pi-2017-07-26],[@b5-pi-2017-07-26]\]. In this context, the need for active management of mental health issues in patients with breast cancer undergoing intensive treatment is of paramount importance \[[@b4-pi-2017-07-26]\].

Compared to the general population, patients with breast cancer patients exhibit a higher prevalence of depressive symptoms and major depressive disorder in the early period following surgery \[[@b6-pi-2017-07-26]\]. Research also indicates that patients with breast cancer are at high risk for depression within the first year of diagnosis \[[@b7-pi-2017-07-26]\], and that around 20--30% of all patients with breast cancer develop psychiatric conditions such as anxiety and depression within the first year after surgery \[[@b8-pi-2017-07-26],[@b9-pi-2017-07-26]\]. Furthermore, approximately one-third of patients who undergo surgical treatment for breast cancer experience depression and anxiety within three months after surgery \[[@b10-pi-2017-07-26]\]. Therefore, screening for patients at high risk for psychological pain in the early stages of breast cancer is critical in order to provide immediate and appropriate intervention, which has been associated with improved quality of life and increased long-term survival rates \[[@b7-pi-2017-07-26]\].

Women who have been treated for breast cancer undergo marked changes in physical appearance, primarily in terms of breast deformity, surgical scarring, and skin degeneration due to radiotherapy \[[@b11-pi-2017-07-26]\]. Fingeret et al. \[[@b12-pi-2017-07-26]\] suggested that various disease and treatment factors that are related to breast cancer (e.g., tumor features, genetic risk, type of surgery, type of reconstruction, time, stage, complications) influence the outcome of body image, which are predicted to be highly associated with psychological pain in patients with breast cancer.

Due to the aforementioned factors, patients experience psychological and physical stress during the process of breast cancer diagnosis and surgery. In such high-stress situations, hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis is known to be associated with the onset of depressive symptoms \[[@b13-pi-2017-07-26]\]. In a psychologically stressful situation, the limbic system, including the hippocampus and amygdala, is activated, and secretion of corticotropin-releasing hormone (CRH) and arginine-vasopressin (AVP) is increased in the hypothalamus. CRH acts on the pituitary gland to induce the secretion of adrenocorticotropic hormone (ACTH), which in turn acts on the adrenal gland to stimulate the production and release of cortisol \[[@b13-pi-2017-07-26]-[@b15-pi-2017-07-26]\]. AVP itself plays a minimal role in stimulating ACTH secretion, but in a synergistic action with CRH, AVP increases ACTH secretion in the pituitary \[[@b16-pi-2017-07-26]\]. Apart from CRH, single nucleotide polymorphisms (SNP) of angiotensin-converting enzyme and vasopressin V1B receptors are known to influence reactions to dexamethasone/CRH testing as well as vulnerability to stress-related depression \[[@b17-pi-2017-07-26]\].

As studies have revealed that various stress factors, such as cancer diagnosis and surgery, contribute to hyperactivity of the HPA axis and that resulting changes in inflammation and immune functions are associated with depression, the importance of stress markers as predictors of depression and anxiety has been highlighted \[[@b14-pi-2017-07-26],[@b15-pi-2017-07-26]\]. Furthermore, research has revealed that treatment of depressive symptoms and subsequent relief of psychological pain normalize the function of the HPA axis \[[@b18-pi-2017-07-26]\].

The objective of the present study is to assess the prevalence of depression and anxiety following breast cancer surgery and to verify the association between blood stress markers (e.g., cortisol) and psychological symptoms.

METHODS
=======

Patients
--------

This study was conducted with female patients who had been diagnosed with and had received surgery for breast cancer at the Breast Center at Busan Paik Hospital. All patients had been referred for psychiatric evaluation between May 2014 and April 2016. Patients who underwent surgery in a small area (i.e., breast needle biopsy and mass excision) were excluded. Information such as history, presence of accompanying illness, and type and range of breast cancer surgery were identified through medical records, and information was verified via patient interviews when medical records contained insufficient data. Informed consent was obtained from all individual participants included in the study. This study was approved by the Institutional Review Board of Busan Paik Hospital, Inje University, Busan, Korea (IRB No. 16-057).

Psychological assessment
------------------------

### Hamilton Rating Scale for Depression (HAM-D)

The HAM-D is the most widely utilized tool for the evaluation of depressive symptoms \[[@b19-pi-2017-07-26]\]. Developed in 1960, the HAM-D is a 17-item clinician-administered assessment scale that is especially sensitive to changes experienced by patients with severe depression, as it emphasizes the physical symptoms of depression. Scores range from 0 to 50 points, with higher scores indicating more severe depressive symptoms. Riedel et al. \[[@b20-pi-2017-07-26]\] considered a score between 0--6 indicative of no depression, 7--17 indicative of mild depression, 18--24 indicative of moderate depression, and greater than 24 indicative of severe depression.

### Hamilton Anxiety Rating Scale (HAM-A)

The HAM-A is a 14-item scale that assesses the severity of anxiety symptoms \[[@b21-pi-2017-07-26]\]. Developed by Hamilton in 1959, the HAM-A involves a semi-structured interview during which the interviewer directly evaluates the patient. The symptoms are broadly categorized into general mental anxiety symptoms, cognitive symptoms, and physical symptoms, which are further subdivided into 14 categories. Scores range from 0--56 points, with higher scores indicating more severe anxiety symptoms. A score between 8--14 indicates mild anxiety, 15--23 indicates moderate anxiety, and greater than 24 indicates severe anxiety \[[@b22-pi-2017-07-26]\].

### Body Image Scale (BIS)

The BIS is a 10-item self-report questionnaire that was developed by Hopwood in 2001 to evaluate body image in patients with cancer \[[@b23-pi-2017-07-26]\]. Five items relate to types of happiness/satisfaction associated with body image, while the remaining five relate to experiences associated with cancer. Patients with more severely distorted body image present with higher scores, with total scores ranging from 0--30 points.

### Rosenberg Self Esteem Scale (RSES)

Developed by Rosenberg \[[@b24-pi-2017-07-26]\], the RSES measures the degree of an individual's self-esteem and self-approval patterns. It includes a total of 10 items, five of which are related to positive self-esteem, while the remaining five are related to negative self-esteem. Scores range from 10--40 points, with higher scores indicating higher levels of self-esteem.

### Stress markers

We measured the concentrations of ACTH, cortisol, AVP, and ACE from blood samples obtained from each patient the morning prior to surgery. This is considered an appropriate time to obtain blood samples for control, as anesthetics, surgical and anesthetic techniques, and postoperative prognosis may act as confounding factors following surgery.

### Statistical analysis

Variables were summarized by frequency and percentage for categorical data and mean±standard deviation for numeric data. Group differences were analyzed using the chi-squared test for categorical data and independent t-test for numeric data. The Pearson's correlation coefficients were estimated in order to investigate the association between predictors and HAM-D/HAM-A scores. The effect of independent variables on HAM-D/HAM-A scores was analyzed using multivariate linear regression. All statistical analyses were performed using SPSS Version 23.0 (IBM Corp., Armonk, NY, USA), and p values less than 0.05 were considered statistically significant.

RESULTS
=======

Characteristics of breast cancer patients
-----------------------------------------

A total of 198 female patients (mean age: 53.1±10.3 years; range: 27--78) were enrolled. The time from the end of surgery to the psychiatric interview ranged from 1--17 days; on average, patients underwent assessment on postoperative day 4.4. The sociodemographic/clinical characteristics of the included patients are summarized in [Table 1](#t1-pi-2017-07-26){ref-type="table"}.

Factors associated with symptoms of depression and anxiety in patients with breast cancer
-----------------------------------------------------------------------------------------

A total of 100 patients (50.5%) were classified with mild or more severe depression (HAM-D≥7), while 21 patients (10.6%) were classified with moderate or more severe depression (HAM-D≥18). A total of 84 patients (42.4%) were classified with mild or more severe anxiety (HAM-A≥8), while 31 patients (15.6%) were classified with moderate or more severe anxiety (HAM-A≥15).

Patients were dichotomized according to HAM-D score (low HAM-D/high HAM-D) using a cut-off of 7. However, no significant association was observed between any demographic or clinical variable and HAM-D score. Patients were dichotomized according to HAM-A score (low HAM-A/high HAM-A) using a cut-off of 8. A significant association between past psychiatric history and HAM-A score was observed. In the low HAM-A group (scores \<8), one patient (0.9%) exhibited past psychiatric history, compared with six patients (7.1%) in the high HAM-A group (scores ≥8) (chi-square p value= 0.018). HAM-A score was not associated with recurrence of breast cancer, treatment history, or surgical method ([Table 2](#t2-pi-2017-07-26){ref-type="table"}).

Association between psychological scores and blood stress markers
-----------------------------------------------------------------

The correlations between HAM-D/HAM-A scores and other predictor variables are summarized in [Table 3](#t3-pi-2017-07-26){ref-type="table"}. HAM-D score was positively correlated with HAM-A (r=0.83, p\< 0.001) and BIS (r=0.29, p\<0.001) score. Furthermore, HAM-D score was negatively correlated with RSES score (r=-0.41, p\<0.001), while HAM-A score was negatively correlated with RSES score (r=-0.27, p\<0.001) and positively correlated with BIS score (r=0.32, p\<0.001).

Analysis of factors that affect symptoms of depression and anxiety
------------------------------------------------------------------

Multivariate linear regression analyses revealed that RSES score was significantly associated with HAM-D score (β=-0.368, p\<0.001), and that HAM-A score was significantly associated with BIS score (β=0.251, p=0.003) ([Table 4](#t4-pi-2017-07-26){ref-type="table"}, [Figures 1](#f1-pi-2017-07-26){ref-type="fig"} and [2](#f2-pi-2017-07-26){ref-type="fig"}).

DISCUSSION
==========

In the present study, we revealed that depression was associated with high anxiety, low self-esteem, and highly distorted body image in patients with breast cancer. The psychological pain experienced by patients with breast cancer is influenced by individual psychological traits, including coping ability in response to stressful situations such as cancer \[[@b9-pi-2017-07-26]\]. Psychologically, patients with cancer experience negative self-evaluation and suppression of/negative emotional responses related to low levels of self-esteem. Previous research has indicated that such psychological coping strategies are associated with depression following breast cancer surgery \[[@b1-pi-2017-07-26],[@b10-pi-2017-07-26],[@b14-pi-2017-07-26],[@b25-pi-2017-07-26]\]. Our results indicate that body image distortion is significantly associated with anxiety, aligning with those of previous studies, which have revealed that body image concerns are associated with depression and anxiety, and ultimately with low quality of life and difficulty in sex life, in patients with breast cancer \[[@b26-pi-2017-07-26],[@b27-pi-2017-07-26]\].

In the present study, anxiety symptoms were significantly associated with psychiatric history but not with type or extent of surgery. Prior studies have reported that depression and anxiety symptoms that result from breast cancer diagnosis decrease to levels similar to those observed in the general population by the 1-year follow-up. However, at the 5-year follow-up, patients tend to be more affected by individual factors (e.g., young age, past psychological history, and lack of social support) than by disease or treatment-related factors (e.g., number of infiltrated axillary lymph nodes, size of tumor, biopsy results, and type of axillary treatment) \[[@b6-pi-2017-07-26],[@b28-pi-2017-07-26]\]. As demonstrated in the present study, factors that exist prior to the diagnosis of breast cancer, such as social relations, psychiatric history, and age, are more highly associated with the onset of depression and anxiety than disease-specific factors \[[@b6-pi-2017-07-26]\]. Furthermore, while several studies have reported that the stage of cancer and tumor grade are not particularly associated with the severity of psychosocial symptoms such as depression and quality of life, some studies \[[@b29-pi-2017-07-26],[@b30-pi-2017-07-26]\] have reported that patients experience high anxiety in stage I, which subsides in stage II but increases again in stages III and IV. The popular theory posits that patients have high anxiety in stage I, as it is their first encounter with cancer, but as the cancer progresses to stage II, they adapt to the disease and their anxiety may decline. Stage III and IV patients, on the other hand, may have higher levels depression and anxiety due to reduced quality of life caused by other treatments, such as chemotherapy and radiotherapy, as well as prolonged treatment. However, these studies \[[@b29-pi-2017-07-26],[@b30-pi-2017-07-26]\] also found that the effect of cancer stage on depression and anxiety is marginal or not impressive, indicating a low clinical significance of the effects of cancer stage.

In the present study, we set the cut-off scores for HAM-D and HAM-A at those corresponding to the presence of at least mild symptoms. Although many patients exhibited mild or more severe symptoms, the proportions of patients exhibiting moderate or severe depression and anxiety were 10.6% and 15.6%, respectively, which were lower than those reported by prior studies \[[@b8-pi-2017-07-26]-[@b10-pi-2017-07-26]\]. These differences in the prevalence of symptoms may be due to differences in time of symptom assessment, as the present study assessed levels of depression and anxiety within three weeks of surgery, while other studies have assessed the symptoms within one year of surgery \[[@b8-pi-2017-07-26],[@b9-pi-2017-07-26]\]. However, our prevalence was similar to that of another Korean study that assessed the prevalence of depression and anxiety within one month of surgery \[[@b31-pi-2017-07-26]\].

Several studies have examined the association among post-breast cancer surgery depression symptoms, HPA axis function, and pro-inflammatory cytokine/immune function \[[@b13-pi-2017-07-26],[@b18-pi-2017-07-26],[@b32-pi-2017-07-26],[@b33-pi-2017-07-26]\]. Seok et al. \[[@b13-pi-2017-07-26]\] reported that preoperative post-dexamethasone serum cortisol level is associated with depressive symptoms in patients with breast cancer, suggesting that the HPA axis may be a valuable biological marker of depression and prognosis. Furthermore, Saxton et al. \[[@b18-pi-2017-07-26]\] reported that early adjustment of lifestyle habits in patients with breast cancer normalizes HPA axis regulation, thereby reducing depressive symptoms. However, in the present study, no correlation was observed between stress markers and depression/anxiety symptoms. This may be due to the cross-sectional design of our study, as a single blood test would have been insufficient to reveal such associations. Furthermore, dexamethasone suppression or dexamethasone/CRH tests are recommended due to their higher sensitivity and predictive ability of HPA axis function than blood ACTH and cortisol levels \[[@b34-pi-2017-07-26]\], but we were unable to utilize these methods in the present study.

Some studies \[[@b35-pi-2017-07-26],[@b36-pi-2017-07-26]\] have reported that there is no reliable relationship between indices pertaining to the HPA axis and measurements of mood, though it remains unclear whether this represents a true lack of correlation or an issue with methodology, as some have argued that conceptualization of mood may be a confounding factor \[[@b37-pi-2017-07-26]\]. Positive or negative mood can be distinguished through state and trait measures of mood, and trait measures of mood have been more highly associated with levels of cortisol than state measures \[[@b37-pi-2017-07-26],[@b38-pi-2017-07-26]\]. However, the present cross-sectional study only measured symptoms at a single time point using the HAM-D and HAM-A, which may have been inadequate for use as trait measures of mood. Hence, in addition to biological markers, a more accurate conceptualization and measurement of mood are required to identify the variables influencing the relationship between mood and HPA axis function.

The present study possesses a few limitations. As we utilized a cross-sectional design, preoperative psychological assessments were not conducted, and we were unable to compare the patients' preoperative and postoperative psychological states. Thus, we could not identify whether the depression and anxiety symptoms that were observed after breast cancer surgery were improved or aggravated by the surgery. Furthermore, we did not track changes in the levels of stress markers. Regardless of the fact that the majority of patients with breast cancer are females, males also experience breast cancer. Considering that men with breast cancer probably have significant mental distress due to the perception that breast cancer is a 'woman's disease', it would be interesting to evaluate psychological symptoms in these patients as well. It is also important and potential limitation of the present study.

The results of our study indicate that about 40--50% of patients with breast cancer exhibit postoperative depression and anxiety, which are related to low levels of self-esteem and distorted body image. Hence, appropriate management of depression and anxiety during the treatment of breast cancer may be conducive to disease treatment and promote increased quality of life.
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###### 

Demographic and clinical data of patients with breast cancer

  Variable                         N (%)/mean±SD
  -------------------------------- ------------------------
  All patients                     198 (100.0)
  Age (years)                      53.1±10.3 (27--78)
  Diabetes mellitus                21 (10.6)
  Hypertension                     38 (19.2)
  Past psychiatric history         7 (3.5)
  BMI                              24.1±3.6 (17.7--36.3)
  Menopause                        108 (54.5)
  Breast cancer family history     11 (5.6)
  Breast cancer recurrence         16 (8.1)
  Prior breast cancer surgery      26 (13.1)
  Prior chemotherapy               32 (16.2)
  Prior radiation therapy          8 (4.0)
  Prior hormone therapy            1 (0.5)
  Prior target therapy             9 (4.5)
  Cancer classification            
   Pathologic type                 
    DCIS                           60 (30.3)
    IDC                            123 (62.1)
    Others                         15 (7.6)
   Cancer staging                  
    IA, IB: 1                      40 (20.2)
    IIA, IIB: 2                    35 (17.7)
    IIIA, IIIB, IIIC: 3            23 (11.6)
    IV: 4                          4 (2.0)
   Molecular subtype               
    Luminal type A                 39 (19.7)
    Luminal type B                 98 (49.5)
    HER 2 positive type            18 (9.1)
    Basal-like type                34 (17.2)
  Surgery type                     
   Simple mastectomy               3 (1.5)
   BCS                             122 (61.6)
   SSM                             52 (26.3)
   MRM                             21 (10.6)
  Axillary lymph node dissection   51 (25.8)
  Body surface area                1.60±0.13 (1.37--2.21)

Values are mean±SD (min-max) for continuous variables. BCS: breast conserving surgery, BMI: body mass index, DCIS: ductal carcinoma *in situ*, HER: human epidermal growth factor receptor, IDC: invasive ductal carcinoma, MRM: modified radical mastectomy, SSM: skin sparing mastectomy

###### 

Association between HAM-D/HAM-A scores and demographic/clinical data of patients with breast cancer

  Variable                         HAM-D       p value     HAM-A   p value                 
  -------------------------------- ----------- ----------- ------- ----------- ----------- -------------------------------------------------------
  Age (years)                      52.8±9.1    53.4±11.4   0.677   53.3±9.5    52.8±11.5   0.709
  Diabetes mellitus                7 (7.1)     14 (14.0)   0.117   9 (7.9)     12 (14.3)   0.149
  Hypertension                     19 (19.4)   19 (19.0)   0.945   24 (21.1)   14 (16.7)   0.439
  Past psychiatric history         1 (1.0)     6 (6.0)     0.058   1 (0.9)     6 (7.1)     0.018^[\*](#tfn1-pi-2017-07-26){ref-type="table-fn"}^
  BMI                              24.5±3.6    23.8±3.6    0.175   24.3±3.5    23.9±3.7    0.368
  Menopause                        56 (57.1)   52 (52.0)   0.467   67 (58.8)   41 (48.8)   0.164
  Breast cancer family history     6 (6.1)     5 (5.0)     0.730   5 (4.4)     6 (7.1)     0.403
  Breast cancer recurrence         11 (11.2)   5 (5.0)     0.108   12 (10.5)   4 (4.8)     0.141
  Prior breast cancer surgery      15 (15.3)   11 (11.0)   0.370   16 (14.0)   10 (11.9)   0.661
  Prior chemotherapy               15 (15.3)   17 (17.0)   0.746   22 (19.3)   10 (11.9)   0.162
  Prior radiation therapy          6 (6.1)     2 (2.0)     0.141   6 (5.3)     2 (2.4)     0.309
  Prior hormone therapy            1 (1.0)     0 (0.0)     0.311   1 (0.9)     0 (0.0)     0.389
  Prior target therapy             5 (5.1)     4 (4.0)     0.710   7 (6.1)     2 (2.4)     0.209
  Cancer classification                                                                    
   Pathologic type                                         0.698                           0.972
    DCIS                           29 (29.6)   31 (31.0)           34 (29.8)   26 (31.0)   
    IDC                            60 (61.2)   63 (63.0)           71 (62.3)   52 (61.9)   
    Others                         9 (9.2)     6 (6.0)             9 (7.9)     6 (7.1)     
   Cancer staging                                          0.444                           0.014^[\*](#tfn1-pi-2017-07-26){ref-type="table-fn"}^
    IA, IB: 1                      16 (33.3)   24 (44.4)           15 (26.8)   25 (54.3)   
    IIA, IIB: 2                    18 (37.5)   17 (31.5)           20 (35.7)   15 (32.6)   
    IIIA, IIIB, IIIC: 3            13 (27.1)   10 (18.5)           18 (32.1)   5 (10.9)    
    IV: 4                          1 (2.1)     3 (5.6)             3 (5.4)     1 (2.2)     
   Molecular subtype                                       0.795                           0.866
    Luminal type A                 20 (21.3)   19 (20.0)           25 (22.7)   14 (17.7)   
    Luminal type B                 49 (52.1)   49 (51.6)           56 (50.9)   42 (53.2)   
    HER 2 positive type            7 (7.4)     11 (11.6)           10 (9.1)    8 (10.1)    
    Basal-like type                18 (19.1)   16 (16.8)           19 (17.3)   15 (19.0)   
  Surgery type                                             0.382                           0.796
   Simple mastectomy               0 (0.0)     3 (3.0)             1 (0.9)     2 (2.4)     
   BCS                             62 (63.3)   60 (60.0)           69 (60.5)   53 (63.1)   
   SSM                             26 (26.5)   26 (26.0)           31 (27.2)   21 (25.0)   
   MRM                             10 (10.2)   11 (11.0)           13 (11.4)   8 (9.5)     
  Axillary lymph node dissection   25 (25.5)   26 (26.0)   0.937   33 (28.9)   18 (21.4)   0.232
  Body surface area                1.62±0.11   1.59±0.14   0.146   1.61±0.11   1.60±0.15   0.810

p\<0.05.

BCS: breast conserving surgery, BMI: body mass index, DCIS: ductal carcinoma in situ, HER: human epidermal growth factor receptor, IDC: invasive ductal carcinoma, MRM: modified radical mastectomy, SSM: skin sparing mastectomy

###### 

Correlation coefficients among depression, anxiety, self-esteem, body image, and serum stress markers

             HAM-D                                                   HAM-A                                                   RESES                                                   BIS     ACTH                                                   AVP     ACE
  ---------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------- ------------------------------------------------------ ------- -------
  HAM-D                                                                                                                                                                                                                                                     
  HAM-A      0.83^[\*](#tfn2-pi-2017-07-26){ref-type="table-fn"}^                                                                                                                                                                                           
  RSES       -0.41^[\*](#tfn2-pi-2017-07-26){ref-type="table-fn"}^   -0.27^[\*](#tfn2-pi-2017-07-26){ref-type="table-fn"}^                                                                                                                                  
  BIS        0.29^[\*](#tfn2-pi-2017-07-26){ref-type="table-fn"}^    0.32^[\*](#tfn2-pi-2017-07-26){ref-type="table-fn"}^    -0.41^[\*](#tfn2-pi-2017-07-26){ref-type="table-fn"}^                                                                          
  ACTH       -0.01                                                   -0.02                                                   0.07                                                    -0.05                                                                  
  AVP        0.02                                                    -0.01                                                   -0.05                                                   0.04    0.06                                                           
  ACE        0.13                                                    0.11                                                    -0.07                                                   0.03    -0.01                                                  -0.02   
  Cortisol   -0.04                                                   -0.09                                                   0.12                                                    -0.08   0.52^[\*](#tfn2-pi-2017-07-26){ref-type="table-fn"}^   0.03    -0.11

p\<0.001.

HAM-D: Hamilton Rating Scale for Depression, HAM-A: Hamilton Anxiety Rating Scale, BIS: Body Image Scale, RSES: Rosenberg Self Esteem Scale, ACTH: adrenocorticotropic hormone, AVP: arginine-vasopressin, ACE: angiotensin-converting enzyme

###### 

Variables predicting HAM-D and HAM-A scores

  Variable    β        t        SE      p       Model statistics                           
  ----------- -------- -------- ------- ------- ------------------ ------- ------- ------- -----
  HAM-D                                         8,155              5.071   0.000   0.207   164
   RSES       -0.368   -4.636   0.095   0.000                                              
   BIS        0.132    1.669    0.082   0.097                                              
   ACTH       0.008    0.100    0.041   0.920                                              
   AVP        -0.009   -0.122   0.170   0.903                                              
   ACE        0.113    1.568    0.032   0.119                                              
   Cortisol   0.012    0.143    0.091   0.887                                              
  HAM-A                                         8,155              3.221   0.002   0.143   164
   RSES       -0.161   -1.957   0.100   0.052                                              
   BIS        0.251    3.050    0.087   0.003                                              
   ACTH       0.033    0.376    0.044   0.708                                              
   AVP        -0.035   -0.464   0.180   0.644                                              
   ACE        0.089    1.182    0.034   0.239                                              
   Cortisol   -0.049   -0.558   0.096   0.578                                              

HAM-D: Hamilton Rating Scale for Depression, HAM-A: Hamilton Anxiety Rating Scale, BIS: Body Image Scale, RSES: Rosenberg Self Esteem Scale, ACTH: adrenocorticotropic hormone, AVP: arginine-vasopressin, ACE: angio
